Trial Profile
A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Avdoralimab (Primary) ; Ezurpimtrostat (Primary) ; Monalizumab (Primary) ; Nivolumab (Primary) ; Tocilizumab (Primary)
- Indications COVID 2019 infections; Haematological malignancies; Pneumonia; Solid tumours
- Focus Therapeutic Use
- Acronyms IMMUNONCOVID; IMMUNONCOVID-20
- 29 Sep 2022 Status changed from active, no longer recruiting to completed.
- 04 Aug 2021 Planned End Date changed from 1 Aug 2021 to 1 Dec 2021.
- 04 Aug 2021 Status changed to active, no longer recruiting.